European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

United Kingdom - English - myHealthbox

chiesi limited - felodipine - prolonged-release tablet - 5 mg - in the management of hypertension and prophylaxis of chronic stable angina pectoris

United Kingdom - English - myHealthbox

chiesi limited - felodipine - prolonged-release tablet - 10 mg - in the management of hypertension and prophylaxis of chronic stable angina pectoris

United Kingdom - English - myHealthbox

chiesi limited - salbutamol sulfate - modified release capsules, hard - 4.80mg - selective beta2 -adrenoceptor agonists for systemic use - continuous symptomatic treatment of asthma and other types of reversible obstructive airways disease

United Kingdom - English - myHealthbox

chiesi limited - salbutamol sulfate - modified release capsules, hard - 9.60mg - selective beta2 -adrenoceptor agonists for systemic use - continuous symptomatic treatment of asthma and other types of reversible obstructive airways disease

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram ; 200microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised inhalation, solution - 200/6 mcg/acutuation - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and beclometasone

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - tobramycin - nebuliser solution - 300/4 milligram(s)/millilitre - other aminoglycosides; tobramycin

United Kingdom - English - myHealthbox

chiesi limited - beclometasone dipropionate, formoterol fumarate dihydrate. - pressurised inhalation solution. - 200/6 micrograms/metered dose - drugs for obstructive airway diseases; adrenergics, inhalants - fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair is indicated in adults.